Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: A case report and review of literature

2013 ◽  
Vol 60 (11) ◽  
pp. E140-E142 ◽  
Author(s):  
Kazuo Sakashita ◽  
Shoji Saito ◽  
Ryu Yanagisawa ◽  
Miyuki Tanaka ◽  
Kentaro Yoshikawa ◽  
...  
Keyword(s):  
Stem Cell ◽  
Case Report ◽  
Dendritic Cell ◽  
Complete Remission ◽  
Plasmacytoid Dendritic Cell ◽  
Skin Involvement ◽  
Review Of Literature ◽  
Hematopoietic Stem ◽  
Cell Neoplasm ◽  
First Complete Remission

Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature

2019 ◽  
Vol 85 ◽  
pp. 106199 ◽  
Author(s):  
Guillaume Beziat ◽  
Loïc Ysebaert ◽  
Clément Gaudin ◽  
Zara Steinmeyer ◽  
Laurent Balardy
Keyword(s):  
Case Report ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Review Of Literature ◽  
Cell Neoplasm

scholarly journals Tagraxofusp Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm With Loss of CD123 Expression: Case and Review of Literature

2021 ◽  
Author(s):  
Rohit Gulati ◽  
Asma Abu-Salah ◽  
Tareq Salous ◽  
Mehdi Nassiri
Keyword(s):  
Dendritic Cell ◽  
Complete Remission ◽  
Plasmacytoid Dendritic Cell ◽  
Primary Treatment ◽  
Resistance Mechanisms ◽  
Review Of Literature ◽  
Elderly Male ◽  
Case Presentation ◽  
Cell Neoplasm ◽  
Targeted Immunotherapy

Abstract Background: Tagraxofusp, a CD123 based targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN showed resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer combination chemotherapies to overcome resistance in BPDCN. Case presentation: Herein we report a case of an elderly male with BPDCN that initially achieved complete remission on primary treatment with tagraxofusp. However, BPDCN relapsed after 1.5 years while on treatment with loss of CD123 expression. Conclusions: This case highlights a potential limitation of current and upcoming tagraxofusp based therapies, at least in a subset of refractory BPDCN. We believe our report will serve as a sentinel to incite future investigations involving alternate resistance mechanisms in BDPCN.

Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4938-4938
Author(s):  
Hongsheng Zhou ◽  
Xian Zhang ◽  
Guopan Yu ◽  
Yongjian Deng ◽  
Qianli Jiang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Dendritic Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Plasmacytoid Dendritic Cell ◽  
Conditioning Regimen ◽  
Preventive Strategy ◽  
Hematopoietic Stem ◽  
Cell Neoplasm

Abstract Abstract 4938 Background Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course,formerly known as blastic natural killer (NK)-cell lymphoma and CD4+/CD56+ hematodermic neoplasm. Here we report 2 cases of blastic plasmacytoid dendritic cell neoplasm that underwent allogeneic stem cell transplantation. Patients and Methods Case one was recognized as acute lymphocyte leukemia and then was revised to BPDC at recurrence, and another initially presented with typical cutaneous involvement and was promptly diagnosed by biopsy. After induction/re-induction and subsequent consolidation chemotherapy, 2 cases of BPDC received HLA identical-sibling donor allogeneic stem cell transplantation (Allo-HSCT) after BU/Cy, TBI/Cy+VP-16 conditioning regimen, respectively. Both achieved rapid hematopietic recovery in 2 weeks. Multi-color labeling flow cytometry was performed to monitor minimal residual disease (MRD) and the patient received donor lymphocyte infusion (DLI) to control primary malignancy as MRD-triggered or preventive strategy. Results Case 1 survived refractory acyclovir-resistant Epstein-Barr virus viremia after rituximab treatment, but failed in DLI-related grade IV graft versus host disease (GVHD) mixed with thrombotic microangiopathy (TMA) on 1 year post-transplantation. Case 2 died from relapse. Conclusion: Allo-HSCT seems to be a promising treatment for aggressive BPDC aided with MRD monitoring and MRD-triggered DLI. GVHD mixed with TMA deserves more attention for treatment of refractory GVHD. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document